Table 2.
List of microsatellite panels using tissue-based MPS strategies
| Study | Panel/No. of tested loci | Seq. Platform | Paired samples | Tool | Tumour type | Analytical performance/reference methods |
|---|---|---|---|---|---|---|
| [180] | 3 In-house panels/3 154, 230, 23 | NextSeq 500 | R | mSINGS, mSILICO | CRC | NA |
| [112] | TruSight™ Oncology 500/130 nc-MNRs | NextSeq™ 550Dx | NR | In-house | 6 cancer types | 98.0% (106) specificity/pentaplex MSI-PCR |
| [108] | OncoPanel AMC version 3/85 MNRs | MiSeq | NR | NA | CRC | 92.1% sensitivity; 100.0% specificity for MSI-H/NA |
| [181] | 5 MNRs; 2 DNRs | MiSeq | R | In-house | CRC | 100.0% sensitivity; 100.0% specificity/pentaplex MSI-PCR or 9 loci NCI/Bethesda panel |
| [109] | 40 unspecified loci | MiSeq | NR | In-house | 7 cancer types | 98.0% (98/100) concordance/pentaplex MSI-PCR |
| [14] | 17 MNRs | MiSeq | NR | In-house | CRC | 100.0% sensitivity; 100.0% specificity/pentaplex MSI-PCR |
| [81] | 1 880 MNRs | In-house FoundationOne assay | NR | In-house | Large cohort | Combined concordance (con.) 97.0% (65/67)/pentaplex MSI-PCR and IHC; 95.0% con./MSI-PCR; 100.0% con./IHC; 97.0% con. with 95.0% sensitivity and 98.0% specificity to comparable methods [101] |
| [182] | BROCA/146 MNRs | HiSeq 2500 | R | mSINGS | Prostate cancer | NA/pentaplex MSI-PCR |
| [107] | smMIPs panel/111 MNRs | NextSeq 500 | NR | mSINGs | CRC, prostate, endometrial cancer | 95.8–100.0% sensitivity; 100.0% specificity/pentaplex MSI-PCR |
| [106] | Caris MI TumourSeek/7 317 | NextSeq | NR | In-house | 26 cancer types | 100.0% sensitivity; 99.9% specificity (CRC), 95.8% sensitivity; 99.4% specificity (all cancer types)/pentaplex MSI-PCR |
| [105] | UW-OncoPlex/15 MNRs | NA | NA | mSINGs | NA | 100.0% sensitivity; 100.0% specificity/pentaplex MSI-PCR |
| [183] | Caris MI TumourSeek | NA | NA | In-house | 12 cancer types | 95.8% sensitivity; 99.4% specificity/pentaplex MSI-PCR |
| [103] | ColonCore/22 MNRs | NA | R | MSI-ColonCore | CRC | 97.9% sensitivity (47/48); 100.0% specificity (37/37)/pentaplex MSI-PCR and IHC |
| [117] | NA | NA | R |
MANTIS, MSIsensor, mSINGs |
6 cancer types | 97.2% sensitivity; 99.7% specificity for MANTIS, 96.5%; 98.7% for MSIsensor, 76.06%; 99.7% for mSINGs/NA |
| [76] | MSK-IMPACT/1000–1500 unspecified loci | Targeted NGS dataset | R | MSIsensor | 66 cancer types | 96.1% sensitivity; 98.5% specificity (MSS vs MSI-H); 100.0% sensitivity; 99.3% specificity (MSI-H in CRCs and uterine endometrioid cancers), 96.6% sensitivity; 100.0% specificity (MSI-H in other tumour types)/pentaplex MSI-PCR |
| [101] | NA | HiSeq 2500 | NR | In-house | CRC | 100.0% sensitivity; 99.0% specificity in detection of MSI-H/pentaplex MSI-PCR |
| [102] | 17 MNRs | MiSeq | NR | mSINGs | 78 cancer types | 97.1% sensitivity (34/35) in MSI positive samples; 100.0% specificity (42/42) in MSI negative samples/pentaplex MSI-PCR |
Explanatory notes: Seq. Platform, sequencing platform; Ref., references; NA, not available; R, required; NR, not required; nc, non-coding; MNRs, mononucleotide repeats; DNRs, dinucleotide repeats